Orthofix Medical Inc. (NASDAQ:OFIX) is a top medical device stock according to analysts, with Barrington analyst raising price target to $17 on August 6. The company reported strong fiscal Q2 results and affirmed its 2025 outlook, supporting the optimistic rating.

Orthofix Medical Inc. (NASDAQ:OFIX) announced fiscal Q2 2025 results on August 5, reporting net sales of $203.1 million, a 2% growth on a reported basis and 4% on a pro forma constant currency basis compared to Q2 2024. U.S. Spine Fixation saw 5% net sales growth and 7% procedure volume growth.

Orthofix Medical Inc. (NASDAQ:OFIX) operates through Global Spine and Global Extremities business segments, providing medical devices. The Global Spine segment includes Bone Growth Therapies, Spinal Implants, and Biologics. The company’s net sales growth continues to show positive trends in its different segments.

Investors see potential in OFIX as an investment, but believe other AI stocks offer greater upside potential and less downside risk. A report on the best short-term AI stock is available for those looking for undervalued opportunities. The company continues to show growth in the medical device industry.

Read more at Yahoo Finance: Barrington Lifts PT on Orthofix Medical (OFIX) to $17 From $16, Keeps an Overweight Rating